SCHEMBL19852464

SCHEMBL19852464

N#Cc1ccccc1OC1CCN(CC2Cc3cccnc3C2)CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR6 P46095 2/20 0.41
PDE10A Q9Y233 1/20 0.40
DRD2 P14416 3/20 0.38
SIGMAR1 Q99720 2/20 0.38
EPHX2 P34913 1/20 0.38
SCD O00767 1/20 0.38
HTR7 P34969 2/20 0.37
HTR2A P28223 2/20 0.37
HTR1A P08908 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
OPRL1 P41146 1/20 0.37
HRH1 P35367 1/20 0.36
CCR3 P51677 1/20 0.36
KCNH2 Q12809 1/20 0.36
HTR2C P28335 1/20 0.36
DCK P27707 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21072474 0.84 OPRL1 (0.47) PDE10ADRD2SIGMAR1SCDHTR7
SCHEMBL19852164 0.84 SIGMAR1 (0.44) PDE10ADRD2SIGMAR1HTR7HTR2A
SCHEMBL19852012 0.82 HRH3 (0.54) SIGMAR1HTR7HRH1CCR3KCNH2
SCHEMBL19852013 0.81 SIGMAR1 (0.42) DRD2SIGMAR1EPHX2HTR7HTR2A
SCHEMBL19838591 0.79 HTR7 (0.44) DRD2SIGMAR1HTR7HTR2AMEN1
Hydrochloric Acid SCHEMBL19839881 0.78 HTR7 (0.43) DRD2SIGMAR1HTR7HTR2AMEN1
SCHEMBL19852467 0.76 PDE4D (0.42) DRD2SIGMAR1HTR7HTR2AHTR2C
SCHEMBL19852421 0.76 HTR2A (0.43) DRD2HTR7HTR2AMEN1KMT2A
SCHEMBL19852154 0.74 OPRK1 (0.44) SIGMAR1HTR7HTR2AHTR1AHRH1
SCHEMBL20068835 0.72 HRH3 (0.59) GPR6PDE10AEPHX2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C GPR6 1549/4885PDE10A 431/4885DRD2 69/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C GPR6 1549/4885PDE10A 431/4885DRD2 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.